In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model
- 1 February 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (2) , 539-550
- https://doi.org/10.1128/aac.01061-07
Abstract
Multiple in vivo studies have characterized the pharmacodynamics of drugs from the triazole and polyene antifungal drug classes. Fewer studies have investigated these pharmacodynamic relationships for the echinocandin drug class. We used a neutropenic murine model of disseminated Candida albicans, Candida tropicalis, and Candida glabrata infection to characterize the time course of activity of the new echinocandin anidulafungin. The pharmacokinetic-pharmacodynamic (PK-PD) indices (the percentage of time that the drug concentration was above the MIC, the ratio of the area under the concentration-time curve from 0 to 24 h [AUC(0-24)] to the MIC, and the ratio of the maximum serum drug concentration [C(max)] to the MIC) were correlated with in vivo efficacy, as measured by organism numbers in kidney cultures after 96 h of therapy. The kinetics following intraperitoneal anidulafungin dosing in neutropenic infected mice were monitored. Peak levels and AUCs were linear over the 16-fold dose range studied. The drug elimination half-life in serum ranged from 14 to 24 h. Single-dose postantifungal-effect studies demonstrated prolonged suppression of organism regrowth after serum anidulafungin levels had fallen below the MIC. Of the four dosing intervals studied, treatment with the more widely spaced dosing regimens was most efficacious, suggesting the C(max)/MIC ratio as the PK-PD index most predictive of efficacy. Nonlinear regression analysis suggested that both the C(max)/MIC and AUC/MIC ratios were strongly predictive of treatment success. Studies were then conducted with 13 additional C. albicans, C. tropicalis, and C. glabrata isolates with various anidulafungin susceptibilities (MICs of anidulafungin for these strains, 0.015 to 2.0 microg/ml) to determine if similar C(max)/MIC and AUC(0-24)/MIC ratios for these isolates were associated with efficacy. The anidulafungin exposures associated with efficacy were similar among Candida species.Keywords
This publication has 52 references indexed in Scilit:
- In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin SusceptibilityAntimicrobial Agents and Chemotherapy, 2006
- Global Surveillance of In Vitro Activity of Micafungin against Candida : a Comparison with Caspofungin by CLSI-Recommended MethodsJournal of Clinical Microbiology, 2006
- Reviews Of Anti‐infective Agents: Anidulafungin: A Novel EchinocandinClinical Infectious Diseases, 2006
- In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously SusceptibleCandida albicansPopulation Examined by Microbiologic and Transcriptional ProfilingAntimicrobial Agents and Chemotherapy, 2006
- Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during TherapyAntimicrobial Agents and Chemotherapy, 2006
- Progressive Esophagitis Caused byCandida albicanswith Reduced Susceptibility to CaspofunginPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility TestingClinical Microbiology Reviews, 2006
- Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitisJournal of Antimicrobial Chemotherapy, 2006
- Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive CandidiasisAntimicrobial Agents and Chemotherapy, 2005
- In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to FluconazoleJournal of Clinical Microbiology, 2005